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insights on model constructs, key data elements/assumptions, and recent mod-
eling advances. Results: Thirty-three HTAs comprising 60 CUAs were considered 
relevant and investigated further. Albeit individual sampling models and discrete 
event simulations have some advantages over Markov models, these three tech-
niques may provide similar cost-effectiveness estimates and were all deemed 
appropriate for HTA submissions. At least ten different structural components 
were identified for which data sources and/or assumptions have evolved over time, 
several of which have a major bearing on model outcomes. The characteristics of 
patients entering the model (e.g. disease severity and prior treatments), assump-
tions about long-term disease progression whilst on treatment and the rebound 
effect upon treatment discontinuation, and mapping of Health Assessment 
Questionnaire and/or pain scores to Quality of Life utility values were repeatedly 
mentioned as key elements affecting the results. ConClusions: A wide variety 
of economic models for the evaluation of bDMARDS in RA have been developed 
and are continuously being refined. Despite recent initiatives to reach consensus 
on how RA models should be designed, substantial differences in the data sources 
and assumptions that are used still remain. This limits the comparability across 
and also generalizability of the various results obtained by using these models 
and poses problems to all stakeholders involved in HTAs.
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objeCtives: One of the major critiques with submitted manufacturer’s cost-
effectiveness models is surrounding the structural uncertainty. However, methods 
dealing with structural uncertainties are not well-developed, even though these 
might have a significant impact on model results. This study investigates the 
impact of structural changes in a National Institute for Health and Care Excellence 
(NICE) single technology appraisal cost-effectiveness model of Erlotinib versus 
Best Supportive Care as a maintenance therapy for patients with non-small cell 
lung cancer. The manufacturer’s model submission was criticised for having a 
“Markov” model not governed by transition probabilities. It considered an inde-
pendent projective survival functions for progression-free survival and overall 
survival, which allowed a negative post-progression survival (PPS) estimate to 
appear in later cycle. Methods: Using published summary survival data, this 
study adopted three approaches, covering both fixed- and time-varying, to esti-
mate health state transition probabilities that are used in a restructured Markov 
model. Results: Unlike for placebo, the parametric approach estimates post-
progression probabilities and probabilities of death for Erlotinib differently than 
fixed-transition approaches. The best fitting curves are achieved for both PPS 
and probability of death across the time for which data were available, but the 
curves start diverging towards the end of this period. The alternative (Markov) 
model which extrapolates the curves forward in time suggests that this differ-
ence between a time-varying and fixed-transition becomes even greater. The 
alternative models produce an Incremental Cost-Effectiveness Ratio (ICER) 
of £54k -£66k per quality adjusted life year (QALY) gain, which is comparable 
to an ICER presented in the MS (£55k/QALY gain). ConClusions: The results 
from restructured alternative models do not suggest different cost-effectiveness 
results to those reported in the manufacturer submission; however, in terms of 
magnitude they vary. This variation in cost-effectiveness results produced by 
restructured models might be crucial for interventions falling near a threshold 
value.
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objeCtives: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic 
disorder characterised by enlarged kidneys and declining renal function. ADPKD 
progression rates are heterogeneous, influenced by age, gender, renal size and 
genotype. Disease models often utilise progression rates derived from published 
studies. This study aimed to compare ADPKD progression, in terms of changes in 
total kidney volume (TKV) and renal function, modelled from summary versus 
patient-level data (PLD), and assess the consistency of predictions with trial obser-
vations. Methods: Regression equations were derived from the TEMPO 3:4 trial 
placebo arm (natural history) to predict annual changes in TKV and estimated glo-
merular filtration rate (eGFR). Candidate covariates included age, gender, ethnicity, 
region/country, TKV and eGFR. Predictions were compared using the PLD regres-
sion equations or linear interpolation of summary rates of change in four patient 
categories. Finally, the model was initiated with published baseline patient pro-
files representing early and late disease from the HALT-PKD trials, and predicted 
progression compared to trial observations. Results: For patients initiated with 
the average TEMPO 3:4 placebo profile, predicted eGFR trajectories based on PLD 
or summary data were similar (average decline: -5.3 and -5.1ml/min/1.73m2/year, 
respectively); however, TKV predictions deviated as TKV exceeded 2,500ml, with 
increasingly rapid growth predicted based on summary data. The model closely 
replicated ADPKD progression among patients with early disease; all predicted 
values within the 95% confidence interval of HALT-PKD observations. In patients 
with late disease, modelled baseline TKV of 1,000-1,500ml led to closest replication 
of eGFR observations (average decline: -3.2 to -4.4, versus -3.9ml/min/1.73m2/year 
during trial). ConClusions: Though predictions based on summary and PLD 
were consistent, the PLD regression equations produced more realistic results at 
extreme values. The availability of relevant PLD to describe the natural history of 
ADPKD progression provides a more robust foundation for disease and economic 
modelling than summary data alone.
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objeCtives: To address the practical and methodological issues associated with 
using low-quality evidence outcomes in health economic modelling. Methods: A 
cost-effectiveness model for disease-modifying drugs (DMDs) in multiple sclerosis 
(MS) in The Netherlands was used to assess how to deal with low-quality evidence 
in health economic modelling. The model adopted a 10-year time horizon and a 
societal perspective. A Markov model was constructed based on EDSS staging in 
MS, including relapse. The central focus was on disease progression — instead of 
relapse — which appeared to be the driver of the cost-effectiveness outcomes. The 
main data source was a recent Cochrane review estimating relative efficacy and 
acceptability of DMDs in relapse-remitting MS. Other data sources included addi-
tional published literature, clinical trials, and official price/tariff lists. Results: The 
analysis based on the Cochrane review data showed that interferon beta-1a-R (Rebif) 
is cost-effective over interferon beta-1a-A (Avonex) (dominant) and interferon beta-
1b (€ 27,654/QALY), but that interferon beta-1a-R is not cost-effective over glatiramer 
acetate. However, for disease progression, the level of evidence is considered very 
low (level 1) for all drugs, except interferon beta-1a-R (moderate - level 3), implying 
unreliable effectiveness outcomes which, consequently, can result in unreliable 
cost-effectiveness outcomes. Two reasonable alternative approaches may be to 
exclude very low evidence from the cost-effectiveness analysis or assume placebo 
efficacy. Alternative analyses, including placebo efficacy for disease progression for 
drugs of which the evidence is labelled very low by Cochrane (all except interferon 
beta-1a-R), strongly impacted outcomes: interferon beta-1a-R was cost-effective 
over interferon beta-1a-A (dominant), interferon beta-1b (€ 6,265), and glatiramer 
acetate (dominant). ConClusions: Inclusion of very low-quality evidence in health 
economic modelling may lead to unreliable cost-effectiveness conclusions. However, 
a gold standard is lacking for handling levels of clinical evidence in health economic 
models. One alternative, presented here, would be to assume placebo efficacy in 
such cases.
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objeCtives: To evaluate different statistical methodologies in a network meta-
analysis (NMA) comparing the effectiveness of interferon-beta (IFNβ ) therapies 
across several endpoints in relapsing-remitting multiple sclerosis (RRMS) to 
determine potential best practices. Methods: A systematic literature review 
(1996-2014) was conducted to identify randomised, controlled trials of FDA- and 
EMA-approved IFNβ DMDs in RRMS, including subcutaneous (SC) IFNβ -1a (44μ g or 
22μ g 3x/wk), SC pegIFNβ -1a (125μ g every 2wks), intramuscular (IM) IFNβ -1a (30μ g 
1x/wk), and SC IFNβ -1b (250μ g EOD). Data were extracted for patients relapse-free, 
patients without disability progression, and patients without new MRI activity 
at study end. A random-effects Bayesian model was utilised for the base case 
analysis, and sensitivity analyses investigated results using different analysis 
frameworks or effects distributions. Results: 644 articles were retrieved; 14 met 
inclusion criteria and reported evaluable data. The evidence networks had few 
connections between nodes, with a maximum of 10 connections for the proportion 
of “patients relapse-free” endpoint. In addition, there were few connections with 
multiple studies linking nodes, with a maximum of 50% (5/10) of connections hav-
ing more than one study on the relapse endpoint, and there were at most two stud-
ies linking any two nodes. Because of the small number of studies linking nodes, 
a random-effects Bayesian model with uninformative priors resulted in wide 
credible intervals, complicating interpretation of results; uncertainty decreased 
using a random-effects Bayesian model with an informative prior as well as with 
a fixed-effects Bayesian model. Estimates for the treatment effects were similar 
across all Bayesian approaches. Utilising a Frequentist approach resulted in similar 
estimates for treatment effects compared to the Bayesian analyses framework, 
although with slightly less uncertainty. ConClusions: While similar estimates 
for treatment effects were found across statistical methodologies, the combi-
nation of a Bayesian approach and a random-effects distribution with informa-
tive prior allowed for methodological robustness while yielding interpretable 
findings.
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objeCtives: Over the last decade, several biologic disease-modifying anti-
rheumatic drugs (bDMARDs) have become available providing additional treat-
ment options for rheumatoid arthritis (RA) patients. This study was conducted 
to identify and compare existing economic models used by health technology 
assessment (HTA) bodies to evaluate bDMARDs. Methods: The HTA Accelerator 
database and websites of HTA agencies (NICE, SMC, NCPE, ZIN, TLV, PBAC, CADTH, 
INESSS, MOHLTC, DECIT-CGATS and AHRQ) were screened to identify assess-
ments of bDMARDs published since 2005 that included a cost-utility analysis 
(CUA). In addition, a targeted literature review was performed to gain further 
